
    
      The study design is a double blind placebo controlled trial that will enroll subjects between
      the ages of 8 - 30 who have had the diagnosis of Type 1 diabetes made 4 - 12 months prior to
      enrollment. A single 14 course of treatment with mAb hOKT3gamma1(Ala-Ala), Teplizumab will be
      given. The primary endpoint is the C-peptide response to a mixed meal at 12 months. A total
      of 60 subjects will be enrolled (30 in the drug treatment and 30 in the placebo groups) at 4
      study sites: Yale University,the University of California at San Francisco, Children's
      Hospital of Philadelphia, and the Barbara Davis Diabetes Center.
    
  